Arbutus Biopharma Corporation

Healthcare · Biotechnology · United States

Last price 4.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 832.94M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inh...